Alpha-6-beta-2-beta-3 nicotinic acetylcholine receptor (α6β2β3 nAChR)

The Alpha-6-beta-2-beta-3 nicotinic acetylcholine receptor is a specialized subtype of the nicotinic receptor family, primarily localized in the dopaminergic neurons of the substantia nigra and ventral tegmental area (Quik et al., 2011; PubMed: 21429113). This receptor complex is a pentameric ligand-gated ion channel composed of alpha-6, beta-2, and beta-3 subunits, which distinguishes it from the more ubiquitous alpha-4-beta-2 subtype found throughout the brain (UniProt: P43681, P17677, Q05941). It plays a critical role in regulating the release of dopamine in the striatum, making it a key target for treating Parkinson's disease and nicotine addiction. Because of its restricted expression pattern, it offers a unique opportunity for developing highly selective drugs with fewer off-target effects compared to broader nicotinic agonists. Dysregulation or loss of these receptors is a hallmark of early-stage Parkinson's disease, and they are also heavily involved in the reinforcing effects of nicotine. Pharmacological agents such as varenicline and nicotine act as agonists at this site, while selective peptide toxins like alpha-conotoxin MII are used in research to characterize its function. Therapeutic strategies targeting this receptor aim to modulate dopaminergic tone to alleviate motor symptoms or reduce drug-seeking behavior.

Other names

CHRNA6/CHRNB2/CHRNB3 receptorAlpha6-beta2-beta3 nicotinic receptorNeuronal acetylcholine receptor alpha-6/beta-2/beta-3Alpha6* nAChR

The receptor functions as a pentameric ligand-gated cation channel; upon binding of an agonist like acetylcholine or nicotine, the channel undergoes a conformational change to open an aqueous pore, allowing the influx of sodium and calcium ions, which results in presynaptic depolarization and the subsequent release of neurotransmitters, particularly dopamine (Gotti et al., 2010; PubMed: 20141292).